InvestorsHub Logo
Followers 88
Posts 6656
Boards Moderated 1
Alias Born 09/18/2009

Re: DCF post# 36359

Tuesday, 05/24/2022 2:59:48 PM

Tuesday, May 24, 2022 2:59:48 PM

Post# of 42811
At least, the fatigue will only be for this drug and the Covid indication. Approvals for lenz and ifab will come more quickly for CAR-T, GvHD, and CMML.

But getting authorized for Covid will take our microcap biotech to the blockbuster revenue level in and of itself.

And I agree that it was very reassuring that TLD is still targeted for Q2 release.